SAR don't have a commercial officer because they don't need one - IMO. CHK1 is being handled by CRUK (who know a thing or two about doing deals) and Aurora is being dealt with by HMU at no cost to SAR. Both are progressing and if I was a big pharma looking to deal, it makes financial sense at this point to wait and see how they progress. Yes, they will pay more by dealing at a later stage, but there will be less risk of paying for something that doesn't get to clinical trials and is therefore worthless.
If either does get that far (a fair assumption based on the last RNS) then becomes a known gamble. Even the largest pharma have failures (research AZD7762 to see how AstraZenica failed after years or research, spending millions on CHK1) but the measurable failure rates become known as all trials are logged and monitored. Before trials start, the information regarding success or failure rates is a bit sketchy.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.